Pα+ Psychedelic Bulletin #162: EQUULUS Therapeutics Emerges from Stealth; Responses to ICER's Draft Evidence Report on Lykos' MDMA; and more...
- EQUULUS Therapeutics Emerges from Stealth with Non-Hallucinogenic Ibogaine Analog as Lead Candidate
- Responses to ICER’s Draft Evidence Report on MDMA-Assisted Psychotherapy for PTSD
- Responses to ICER’s Draft Evidence Report on MDMA-Assisted Psychotherapy for PTSD
- Jennifer Mitchell, University of California San Francisco
- Erick Turner, Oregon Health & Science University, former psychiatric drugs reviewer at FDA
- Michael Ostacher, Stanford University
- Other Stories
- An Update on Health Canada’s Special Access Program
- Beckley Psytech Publishes Phase I Study of Intranasal 5-MeO-DMT (BPL-003)
- Misc. News
- In Case You Missed It
Companies, organisations and drug candidates mentioned in this Bulletin: EQUULUS Therapeutics; EQL-101; EQL-201; Gilgamesh Pharmaceuticals; DemeRx; atai Life Sciences; Delix Therapeutics; CaaMTech; Lykos Therapeutics; Beckley Psytech; BPL-003; Compass Pathways; Clairvoyant Therapeutics...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In